Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment

Part of paid clinical trials in Galveston, Texas.

Sponsor
The University of Texas Medical Branch, Galveston
Study ID
NCT06800092
Phase
PHASE2/PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cancer

Eligibility Criteria

Sex
FEMALE
Age
30 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Sildenafil — DRUG
    Sildenafil, 50mg, daily

Study Details

This study is examining the effects of standard of care cancer treatment as well as a medication called Sildenafil, on the cancer associated fatigue, cognition and the gut microbiome.

Key Dates

Start date
Jun 15, 2027
Status verified
May 2026
Primary completion
Jun 1, 2030
Completion
Jun 1, 2030

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • No Intervention: Standard of Care Treatment
    standard of care treatment
  • Experimental: Standard of Care Treatment and Sildenafil
    Sildenafil, 50mg, daily for duration of the standard of care treatment

Primary Outcome Measure

Fatigue and Cognition as measured by the Fatigue and Altered Cognition Scale at baseline [ Time Frame: Baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Texas Medical BranchGalvestonTexas77555
Kate Randolph, BS
[email protected]
409-223-7891
Melinda Sheffield-Moore, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Galveston, TX

By research site
The University of Texas Medical Branch· Galveston, TX

Related Studies